Intestinal Permeability, Vitamin A Absorption and Serum Alpha-Tocopherol in Gastrointestinal Stromal Tumor Patients Treated with Imatinib

DOI Web Site 参考文献69件
  • MELICHAR Bohuslav
    Department of Oncology, Palacký University Medical School and Teaching Hospital Institute of Experimental Neurosurgery, Charles University Medical School and Teaching Hospital
  • KAŠPAROVÁ Markéta
    Department of Gerontology and Metabolic Care, Charles University Medical School and Teaching Hospital Department of Analytical Chemistry, Charles University School of Pharmacy
  • KALÁBOVÁ Hana
    Department of Oncology and Radiotherapy, Charles University Medical School and Teaching Hospital
  • DVORÁK Josef
    Department of Oncology and Radiotherapy, Charles University Medical School and Teaching Hospital
  • HYŠPLER Radomír
    Department of Gerontology and Metabolic Care, Charles University Medical School and Teaching Hospital
  • TICHÁ Alena
    Department of Gerontology and Metabolic Care, Charles University Medical School and Teaching Hospital
  • KRCMOVÁ Lenka
    Department of Gerontology and Metabolic Care, Charles University Medical School and Teaching Hospital Department of Analytical Chemistry, Charles University School of Pharmacy
  • PLÍŠEK Jirí
    Department of Gerontology and Metabolic Care, Charles University Medical School and Teaching Hospital Department of Analytical Chemistry, Charles University School of Pharmacy
  • HOLECKOVÁ Petra
    Institute of Experimental Neurosurgery, Charles University Medical School and Teaching Hospital
  • SOLICHOVÁ Dagmar
    Department of Gerontology and Metabolic Care, Charles University Medical School and Teaching Hospital

この論文をさがす

抄録

Administration of imatinib is the therapy of choice in patients with advanced (inoperable) or metastatic gastrointestinal stromal tumors (GIST). Gastrointestinal toxicity is one of the most common side effects of anticancer therapy, including imatinib. Measurement of intestinal permeability represents a method of noninvasive laboratory assessment of gastrointestinal toxicity. We have measured intestinal permeability (by determining absorption of lactulose, mannitol and xylose), vitamin A absorption and serum alpha-tocopherol in 16 patients with advanced/metastatic GIST treated with imatinib. Lactulose/mannitol and lactulose/xylose ratios as well as parameters of vitamin A absorption did not change significantly during the treatment, but a significant decrease of alpha-tocopherol was observed. We conclude that, in contrast to most other anticancer agents studied so far, imatinib does not have an effect on intestinal permeability. No effect on vitamin A absorption was observed, but serum alpha-tocopherol decreased significantly during the treatment.

収録刊行物

参考文献 (69)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ